JA

Jenn Adams

Chief Executive Officer at August Bioservices

Nashville, Tennessee

Invests in

  • Min Investment:

    $5,000,000.00
  • Max Investment:

    $50,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • Chief Executive Officer

    2020

    August Bioservices is a CDMO comprised of a team of highly experienced scientists and professionals, providing a comprehensive service offering to advance drug discovery, pharmaceutical development, and manufacturing for the pharmaceutical and biotechnology industries. August Bioservices is uniquely positioned to support individual projects, or to serve as an extension of its customers’ development teams. August Bioservices is scaling its capabilities to support commercial liquid and lyophilized vial filling demand, prefilled syringe & cartridge filling and IV Bag filling and terminal sterilization.

2019

  • Senior Advisor

    2019

    I am responsible for developing and advising new healthcare tech-enabled businesses through a combination of building from scratch and investing in early- and growth-stage companies. Together with the exceptional investment team at Oak HC/FT, we will focus on enabling companies and entrepreneurs who provide value through patient-centric solutions.

  • Member Board Of Directors

    2021

2008 - 2018

  • SVP & President, Clinical Product Solutions

    2015 - 2018

    Led the 2000-employee Clinical Products Solutions business with full P&L responsibility for finance, sales, marketing, operations, supply chain, business development and human resources.

  • Vice President Sales/National Accounts

    2008 - 2015

    Drove commercial growth for this PE backed start-up in the US market. Captured double digit growth YoY, catapulting annual revenue from $58M to $700M. Reported to the CEO and led commercial team of 85 in sales, national accounts and inside sales for the acute care, hospital market segment and ambulatory surgery center markets.

2004 - 2008

  • VP Sales

    2004 - 2008

    Led sales, clinical education and sales training functions for Baxter’s $270M US Transfusion Therapies division following Fenwal’s divestiture from Baxter. Managed a team of 150 employees and led the seamless transition of commercial business to a private, stand-alone business following its acquisition by a PE firm.

1991 - 2004

  • Senior Director Of Marketing

    2001 - 2004

    Designed a strategic marketing plan for 2 U.S. businesses, which delivered a combined $600M in sales. Managed a team of 23 marketing professionals in creation of franchise level strategic plans and marketing plans within the US infusion systems market space.

  • AVP Sales

    1999 - 2001

    Led Sales team of 6 Acute Care Region Managers and 55 Territory Managers in Baxter's Infusion Systems division. Responsible for annual revenue contribution of $303M in capital equipment. Additionally, led a team in the Alternate Site business that included a Region Manager and 8 territory managers with a combined hardware budget of $16M.

  • Early Career Experience - Progessive roles in Sales and Marketing

    1991 - 1999

    Held multiple roles with increasing responsibility within the Sales and Marketing functions of Baxter's Medication Delivery Business.